Budesonide as Topical Therapy for Eosinophilic Esophagitis
ACG Guideline Recommendations
The 2025 ACG Clinical Guideline recommends topical corticosteroids, including budesonide, as a first-line treatment option for eosinophilic esophagitis 1. The guideline positions swallowed topical steroids alongside proton pump inhibitors, empiric diet elimination, biologics, and esophageal dilation as recommended treatments for EoE.
Key Treatment Principles
The guideline emphasizes that topical steroids work by delivering corticosteroid directly to the esophageal mucosa rather than systemically. Budesonide must be swallowed (not inhaled) to coat the esophagus and achieve therapeutic effect 1.
Preparation Methods for Off-Label Budesonide
Since budesonide was not originally formulated for esophageal delivery, clinicians have historically used off-label compounding methods to create viscous preparations:
Traditional Compounding Approach
Budesonide viscous solution (BVS) is prepared by mixing:
- Budesonide respules (typically used for nebulization)
- With a viscosity-enhancing agent (such as sucralose, honey, or other thickening agents)
- To create a slurry that adheres to the esophageal mucosa during swallowing
The standard induction dosing is 1 mg twice daily, though the guideline notes that maintenance therapy dosing remains an area of uncertainty 2.
Alternative Delivery Methods
Recent evidence describes additional off-label approaches:
- Fluticasone nasal spray mixed with honey has been reported as a patient-led, low-cost alternative 3
- Fluticasone metered-dose inhalers (swallowed, not inhaled) remain widely used due to cost barriers 3
FDA-Approved Formulation
As of 2024, an FDA-approved budesonide oral suspension (BOS) is now available, eliminating the need for compounding 4. Real-world data show:
- 73% achieved histologic response (<15 eos/hpf)
- 64% achieved endoscopic response
- 78% reported global symptom improvement
- However, only 65% of prescribed patients could fill their prescription due to insurance barriers 4
Administration Instructions
Critical administration details:
- Swallow the preparation slowly without water immediately after
- Do not eat or drink for 30-60 minutes after administration
- Administer after meals to maximize esophageal contact time
- Avoid grapefruit juice, which increases systemic absorption 5
Efficacy Data
Budesonide demonstrates robust efficacy with meta-analysis showing:
- Histologic remission: RR 26.85 (95% CI: 13.72-52.56)
- Significant reduction in peak eosinophil counts
- Clinical symptom improvement: RR 1.58 (95% CI: 1.03-2.42)
- Important caveat: Does not reverse established fibrosis 6
Safety Considerations
Common adverse effects include:
- Oropharyngeal candidiasis (most common localized infection) 6
- Transient cortisol suppression with long-term use 6
- Generally comparable adverse event profile to placebo overall 6
Monitor for:
- Signs of adrenal suppression during chronic use (fatigue, weakness, nausea, hypotension) 5
- Opportunistic infections, particularly in immunocompromised patients 5
- Avoid exposure to varicella and measles during treatment 5
Maintenance Therapy Considerations
The guideline acknowledges significant uncertainty in maintenance dosing 2. A small trial using low-dose budesonide 0.25 mg twice daily showed only 36% maintained histologic remission at 1 year, suggesting this dose may be insufficient 2. Budesonide orodispersible tablets (BOT) at 1 mg once or twice daily have shown effectiveness for maintenance after initial BVS therapy, with improved histologic remission rates and quality of life 7.
Practical Algorithm for Maintenance
- Continue induction-dose topical steroids (1 mg twice daily) if well-tolerated
- Consider dose reduction only after achieving sustained remission
- If using reduced maintenance dosing, monitor closely for histologic recurrence
- Alternative: Switch to FDA-approved BOT formulation for convenience 7
Common Pitfalls
- Do not use oral/systemic budesonide formulations (extended-release tablets for Crohn's disease or ulcerative colitis) - these are absorbed in the small intestine and do not treat esophageal inflammation 5
- Do not inhale the medication - it must be swallowed to coat the esophagus
- Esophageal dilation alone does not address inflammation and should not replace anti-inflammatory therapy 2
- Insurance barriers remain significant for FDA-approved formulations, necessitating familiarity with off-label compounding 3, 4